These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 4603552)

  • 1. [Further experience with the long-term treatment with aminoglutethimide in hyperfunction of the adrenal cortex (author's transl)].
    Marek J; Horký K; Gregorová I; Motlík K
    Sb Lek; 1974 Aug; 76(7):200-13. PubMed ID: 4603552
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effect of aminoglutethimide in the treatment of adrenal gland hyperfunction].
    Neumann P; Knappe G; Stahl F; Kublun G; Bruns W; Wulfert P
    Z Gesamte Inn Med; 1979 May; 34(9):247-53. PubMed ID: 225896
    [No Abstract]   [Full Text] [Related]  

  • 3. The treatment of congenital adrenal hyperplasia with aminoglutethimide.
    Hamilton W
    Q J Med; 1971 Oct; 40(160):568-9. PubMed ID: 5157412
    [No Abstract]   [Full Text] [Related]  

  • 4. [O.p. DDD (lysodren) in treatment of adrenal cortex hyperfunction in childhood].
    Keller E; Willgerodt H; Teichmann B; Hoepffner W
    Kinderarztl Prax; 1981 Aug; 49(8):436-41. PubMed ID: 7289414
    [No Abstract]   [Full Text] [Related]  

  • 5. [Preliminary results of treatment of hypercorticism with aminoglutethimide].
    Chen JL
    Zhonghua Nei Ke Za Zhi; 1982 Dec; 21(12):747-9, 777-8. PubMed ID: 7182138
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical and biological study of an inhibitor of adrenocortical hormone synthesis: aminoglutethinide].
    Philbert M; Laudat MH; Laudat P; Bricaire H
    Ann Endocrinol (Paris); 1968; 29(2):189-210. PubMed ID: 4298418
    [No Abstract]   [Full Text] [Related]  

  • 7. [Experimental and clinical studies of adrenal cortex hyperfunction].
    Kumagai A
    Nihon Hinyokika Gakkai Zasshi; 1973 Sep; 64(9):697-700. PubMed ID: 4797528
    [No Abstract]   [Full Text] [Related]  

  • 8. [Medical therapy of hyperadrenalism].
    Raith L
    Minerva Med; 1973 Mar; 64(14):682-4. PubMed ID: 4350585
    [No Abstract]   [Full Text] [Related]  

  • 9. [Corticosteroidogenesis inhibitors. II. A new cortico-adrenal inhibitor: amino-glutethimide (16,038Ba)].
    Philbert M; Luton JP; Mathieu de Fossey B; Bricaire H
    Presse Med (1893); 1968 May; 76(23):1107-10. PubMed ID: 5657304
    [No Abstract]   [Full Text] [Related]  

  • 10. Adrenocortical steroidogenesis and aminoglutethimide (A. G.). II. Cytochemical and ultrastructural changes. Pratical and theoretical values.
    Touitou Y; Legrand JC; Desgrez P
    Biomedicine; 1973 Jul; 18(4):272-8. PubMed ID: 4373092
    [No Abstract]   [Full Text] [Related]  

  • 11. [Recovery or remission of Cushing's disease following long term administration of OP'DDD in seventeen patients (author's transl)].
    Luton JP; Remy JM; Valcke JC; Laudat P; Bricaire H
    Ann Endocrinol (Paris); 1973; 34(4):351-76. PubMed ID: 4360563
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anesthesiological assistance of adrenal surgery (part 1)].
    Neĭmark MI; Kalinin AP; Vetshev PS
    Khirurgiia (Mosk); 2004; (1):64-7. PubMed ID: 14989239
    [No Abstract]   [Full Text] [Related]  

  • 13. [Present knowledge on the treatment of Cushing's syndrome].
    Bricaire H; Albeaux-Fernet M; Lumbroso P; Netter A; Sebaoun J
    Presse Med (1893); 1969 Nov; 77(46):1665-8. PubMed ID: 5380390
    [No Abstract]   [Full Text] [Related]  

  • 14. Aminoglutethimide: a "side-effect" turned to therapeutic advantage.
    Hughss SW; Burley DM
    Postgrad Med J; 1970 Jul; 46(537):409-16. PubMed ID: 4920933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New data on the pathogenesis of steroid-induced osteoporosis: consequences for therapy and prevention].
    Hüfner M; Siggelkow H
    Dtsch Med Wochenschr; 2003 Jul; 128(30):1602-8. PubMed ID: 12884149
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical approach to and treatment of various forms of surgically verified forms of hypercorticism (author's transl)].
    Oravec D; Moravec R; Ohrádka B; Hostýn L
    Cas Lek Cesk; 1975 Oct; 114(42):1299-301. PubMed ID: 1192453
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential diagnosis of primary and pseudoprimary hyperaldosteronism.
    Horký K; Gregorová I; Silinková-Malková E; Vancura J
    Rev Czech Med; 1976; 22(4):181-93. PubMed ID: 996300
    [No Abstract]   [Full Text] [Related]  

  • 18. [Role of aminoglutethimide in the treatment of adrenal hyperfunction].
    Kasperlik-Załuska A; Migdalska B; Jeske W; Wiśniewska-Woźniak T
    Pol Arch Med Wewn; 1986 Dec; 76(5-6):249-57. PubMed ID: 3299304
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of cushing's disease with cypropheptadine (author's transl)].
    Michelsen H; Contreras P; Bradford I; Rojas A
    Rev Med Chil; 1977 Jun; 105(6):380-3. PubMed ID: 331429
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical experiences with aminoglutethimide (Elipten), a new inhibitor of steroid biosynthesis in the adrenal gland].
    Horký K; Küchel O; Gregorová I; Jiránková J; Matys Z
    Schweiz Med Wochenschr; 1968 Nov; 98(47):1843-51. PubMed ID: 4236505
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.